Iga Swiatek's doping controversy takes another turn as WADA weighs possible appeal

The World Anti-Doping Agency (WADA) has confirmed that its investigation into Iga Swiatek remains ongoing following the Polish player's doping controversy, as reported by Ubitennis.

The five-time Grand Slam champion failed an anti-doping test in August 2024, which detected trimetazidine in her system. Following an investigation, the ITIA (International Tennis Integrity Agency) imposed a one-month suspension on the current World No. 2, who claimed that the presence of TMZ in her body was due to a contaminated melatonin sleep product.

Read also

“It's smarter to focus on tennis and the ranking will come after that”: Iga Swiatek stays grounded despite chance to reclaim No. 1 spot

Swiatek accepted the one-month suspension, serving it from September 12 to October 4, which prevented her from participating in the Asian Swing. After appealing, she returned to competition, although she still had eight days left to serve, which she completed at the start of the off-season.

Following the ITIA’s decision, Poland’s National Anti-Doping Agency announced it would not appeal. However, Ubitennis recently reported that WADA is considering appealing the decision to the Court of Arbitration for Sport (CAS). WADA has until January 21 to decide.

Read also

“Suspension may be coming”: Former doubles legendary player casts doubt about Jannik Sinner’s future ahead of Australian Open

With just days left before the deadline, Ubitennis confirmed that WADA is still reviewing the decision. “WADA has no comment to make about the specifics of the Swiatek case as it remains under review,” the agency stated.

WADA had previously intervened in the case of Jannik Sinner, appealing ITIA’s decision not to impose a suspension. WADA requested a suspension of one to two years for the current World No. 1. The outcome of that case is still pending, with Sinner at risk of facing a ban.

Subscribe to our Newsletter

Unlock your ultimate tennis experience—subscribe today for exclusive access to top stories.

Subscribe